Egalet Corporation (NASDAQ:EGLT) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Egalet Corporation (NASDAQ:EGLT) lost -10.91 Percent and closed its previous trading session at $0.36. The stock traded with the average Volume of 708.4 Million at the end of last session.
Egalet Corporation (NASDAQ:EGLT) has the Market Capitalization of 21.44 Million. The Stock has its 52-week High of $1.590 and 52-Week Low of $0.260 and it touched its 52-week high on 09/18/17 and 52-Week Low on 07/31/18
The company reported its last earnings Actual EPS of $-0.22/share. While, the analyst predicted that the company could provide an EPS of $-0.28/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.06/share which shows an Earnings Surprise of 21.4 Percent.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated Egalet Corporation (NASDAQ:EGLT) as Buy, 0 analysts given Outperform signal, 2 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -2.26% where SMA50 and SMA200 are -11.93% and -51.33% respectively.
The company shows its Return on Assets (ROA) value of -46.9%. The Return on Equity (ROE) value stands at 152.2%. While it’s Return on Investment (ROI) value is -90.7%.
Egalet Corporation (NASDAQ:EGLT) currently has a Weekly Volatility of 34.59% percent while its Monthly Volatility is at 19.20% percent. While talking about Performance of the Stock, Egalet Corporation currently has a Weekly performance of 1.83%, monthly performance percentage is -7.29 percent, Quarterly performance is -44.54 percent, 6 months performance shows a percent value of -55.77% and Yearly Performance is -68.48 percent.
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom.